Key result
Direct oral anticoagulants such as rivaroxaban, apixaban, and dabigatran offer practical advantages over conventional agents for VTE prevention after hip or knee arthroplasty, including oral administration and no need for routine coagulation monitoring.
Why the study?
What is the optimal practical management of new oral anticoagulants for the prevention of venous thromboembolism in adult patients after elective hip or knee arthroplasty?
Population
Adult patients after elective hip or knee arthroplasty
Comparison
New oral anticoagulants vs Conventional anticoagulants
Design
Review
Authors
Loading...
May guide DOAC selection post-arthroplasty; leaves open head-to-head efficacy and safety data.
What is the optimal practical management of new oral anticoagulants for the prevention of venous thromboembolism in adult patients after elective hip or knee arthroplasty?
This review provides practical guidance and single-institution experience on managing new oral anticoagulants for VTE prevention following hip or knee arthroplasty.
Klauser et al. (2013) conducted a review in Venous thromboembolism prevention after total hip or total knee arthroplasty. Direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) vs. Conventional anticoagulants (LMWH, UFH, VKAs) was evaluated. Direct oral anticoagulants such as rivaroxaban, apixaban, and dabigatran offer practical advantages over conventional agents for VTE prevention after hip or knee arthroplasty, including oral administration and no need for routine coagulation monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: